- Home
- GLPG vs VERA Comparison
GLPG vs VERA Comparison
Compare GLPG & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLPG
- VERA
- Stock Information
- Founded
- GLPG 1999
- VERA 2016
- Country
- GLPG Belgium
- VERA United States
- Employees
- GLPG N/A
- VERA N/A
- Industry
- GLPG Biotechnology: Pharmaceutical Preparations
- VERA Biotechnology: Pharmaceutical Preparations
- Sector
- GLPG Health Care
- VERA Health Care
- Exchange
- GLPG Nasdaq
- VERA Nasdaq
- Market Cap
- GLPG 2.1B
- VERA 1.7B
- IPO Year
- GLPG 2005
- VERA 2021
- Fundamental
- Price
- GLPG $34.45
- VERA $30.72
- Analyst Decision
- GLPG Sell
- VERA Buy
- Analyst Count
- GLPG 3
- VERA 8
- Target Price
- GLPG $26.00
- VERA $64.29
- AVG Volume (30 Days)
- GLPG 203.5K
- VERA 1.5M
- Earning Date
- GLPG 10-29-2025
- VERA 11-06-2025
- Dividend Yield
- GLPG N/A
- VERA N/A
- EPS Growth
- GLPG N/A
- VERA N/A
- EPS
- GLPG N/A
- VERA N/A
- Revenue
- GLPG $323,674,692.00
- VERA N/A
- Revenue This Year
- GLPG $1.77
- VERA N/A
- Revenue Next Year
- GLPG $0.44
- VERA N/A
- P/E Ratio
- GLPG N/A
- VERA N/A
- Revenue Growth
- GLPG 5.43
- VERA N/A
- 52 Week Low
- GLPG $22.36
- VERA $18.53
- 52 Week High
- GLPG $37.78
- VERA $51.61
- Technical
- Relative Strength Index (RSI)
- GLPG 53.87
- VERA 73.97
- Support Level
- GLPG $32.37
- VERA $28.48
- Resistance Level
- GLPG $37.78
- VERA $31.80
- Average True Range (ATR)
- GLPG 0.77
- VERA 1.32
- MACD
- GLPG 0.00
- VERA 0.22
- Stochastic Oscillator
- GLPG 39.37
- VERA 82.75
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.
About VERA Vera Therapeutics Inc.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.